Log in

Kindred Biosciences Stock Forecast, Price & News

-0.08 (-1.60 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $4.92
50-Day Range
MA: $4.29
52-Week Range
Now: $4.92
Volume120,264 shs
Average Volume311,904 shs
Market Capitalization$193.69 million
P/E RatioN/A
Dividend YieldN/A
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Read More
Kindred Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KIN



Sales & Book Value

Annual Sales$4.26 million
Book Value$2.10 per share


Net Income$-61,390,000.00


Market Cap$193.69 million
Next Earnings Date11/10/2020 (Estimated)
-0.08 (-1.60 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

How has Kindred Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KIN stock has decreased by 39.2% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Kindred Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kindred Biosciences

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Kindred Biosciences

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.00 by $0.65. The biopharmaceutical company had revenue of $39.57 million for the quarter, compared to the consensus estimate of $19.77 million. Kindred Biosciences had a negative net margin of 69.69% and a negative return on equity of 28.14%.
View Kindred Biosciences' earnings history

What price target have analysts set for KIN?

5 equities research analysts have issued 12-month price targets for Kindred Biosciences' stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Kindred Biosciences' stock price to reach $11.00 in the next year. This suggests a possible upside of 123.6% from the stock's current price.
View analysts' price targets for Kindred Biosciences

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a decline in short interest in August. As of August 14th, there was short interest totaling 593,400 shares, a decline of 14.9% from the July 30th total of 696,900 shares. Based on an average trading volume of 400,700 shares, the short-interest ratio is currently 1.5 days. Approximately 1.6% of the shares of the company are short sold.
View Kindred Biosciences' Short Interest

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Novavax (NVAX), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Canopy Growth (CGC), InVitae (NVTA) and Opko Health (OPK).

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.38%), Nuveen Asset Management LLC (0.36%), UBS Group AG (0.33%), Goldman Sachs Group Inc. (0.27%), Charles Schwab Investment Management Inc. (0.26%) and Hound Partners LLC (0.20%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin.
View institutional ownership trends for Kindred Biosciences

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., and WINTON GROUP Ltd.
View insider buying and selling activity for Kindred Biosciences

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was purchased by a variety of institutional investors in the last quarter, including Hound Partners LLC, Goldman Sachs Group Inc., Cim Investment Mangement Inc., Tudor Investment Corp Et Al, SG Americas Securities LLC, Bank of New York Mellon Corp, State of Wisconsin Investment Board, and Nuveen Asset Management LLC.
View insider buying and selling activity for Kindred Biosciences

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $4.92.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $193.69 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is kindredbio.com.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.